EL7.AI
Strategy BuilderCOT DataAdvanced NewsResearchNewEarnings CalendarEconomic Calendar
We use cookiesPrivacy Policy
EL7.AIEL7.AI

AI Financial Intelligence
Professional analysis of central bank decisions

© 2026 EL7.AI. All rights reserved.

Markets

  • News
  • Forex
  • Stocks
  • Crypto
  • Gold
  • Commodities
  • Indices
  • ETFs

Analysis

  • Fed
  • ECB
  • BLS
  • COT
  • Economic Calendar

Learn

  • Service Guide
  • Oil

Company

  • About
  • Contact
  • Data Methodology
  • AI Disclosure
  • Pricing
  • Enterprise
  • Terms
  • Privacy
  • Security
  • WhatsApp
Status data is currently unavailable

The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

Home
Stocks
Ecolab Inc.
EL7 Factor Analysis
How we score this
Overall65
Strong — clearly above market medianHigh FlyerF 6/9SafeBetter than 65% of Market stocks, per EL7's model
FactorScoreDistributionValueAvgRank
▸
Valuation
24
37.0x▼17.7xBottom tier
▸
Growth
60
7.1%7.1%Around median
▸
Quality
74
11.5%▲4.5%Top tier
▸
Safety
66
2.1x▲2.6xAround median
▸
Capital Return
35
1.03%▼2.16%Bottom tier
▸
Momentum
62
7.6%▲2.1%Around median
▸
Sentiment
83
17▲3Top tier
ECL

ECL Ecolab Inc.

Ecolab Inc. · NYSE
Market Closed
276.22
▲ ⁦+2.31%⁩ (+6.24)
Market Cap$76.0B
Beta0.89
52w Low52w High
243.15309.27
Last Week
⁦+0.59%⁩
Last Month
⁦-1.87%⁩
Last 3 Months
⁦+2.55%⁩
Last Year
⁦+4.30%⁩
Fair Value
Current price$276
Analyst target · 5 analysts
$331
⁦+20%⁩
See it undervalued
Range ⁦$275–$360⁩
vs
DCF (estimate)
$102
⁦-63%⁩
Sees it clearly overvalued
⁦8.3⁩% discount · ⁦4⁩% growth
Bottom lineThe two methods disagree — estimate range ⁦$102–$331⁩.

Estimates — analyst targets and a simplified DCF, not investment advice.

Compare in the screener
Premium content

Get Your Premium Account Now

  • Stock Deep Analysis
  • The Advanced News Platform
Recommended
Annual plan
$17/mo
Monthly plan
$29/mo

Analyst Consensus

This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.

Price Target· 5 analysts setting price target
$326.13
⁦+18.1%⁩
Current Price $276.22·Median $331.00
Low
$275.00
High
$360.00
Current price
$276.22
Average target
$326.13
Street summary

Stable Targets Amid Narrower Coverage

The consensus price target has not changed over the last 30 days, remaining at 326.13, above the current price of 269.98. Estimates range from 275 to 360, while the median is 331; this reflects notable divergence among analysts despite the overall outlook remaining above the current price. However, the number of analysts fell from 13 to 5, reducing the breadth of the sample and increasing uncertainty about how representative the consensus is.

As of 2026-09-21
Revisions momentum · 30d
⁦0.0%⁩
Average rating
★ 4.04
Buy
Analyst coverage
⁦24 (-8)⁩
Buy conviction
83%
High
Target dispersion
31%
Wide
Analyst ratings over time24 analysts rating
5
15
4
Strong BuyBuyHoldSellStrong Sell
Rating trend — last 12 months3.62 → 4.04
Recent analyst moves
  • = Reiterate2026-07-29
    UBS
    Buy
  • = Reiterate2026-07-29
    BMO Capital
    Outperform
  • ⬆ Upgrade2026-07-17
    Oppenheimer
    Outperform
Premium content
Key Financials

Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.

StockSector medianSector averagetypical sector range
MetricValuePosition within sectorVerdict
  • P/E (TTM)
    36.98x
    4.89x39.11x
    Above average
  • Forward P/E
    30.44x
    3.81x30.52x
    Very expensive
  • EV / EBITDA
    22.16x
    2.63x21.05x
    Expensive
  • FCF Yield
    2.4%
    -20.9%9.2%
    Strong
  • Revenue Growth YoY
    7.1%
    -21.5%91.3%
    Below average
  • EPS Growth YoY
    13.4%
    -253.8%189.1%
    Above average
  • Gross Margin
    44.1%
    7.2%58.9%
    Strong
  • ROIC
    11.5%
    -53.0%20.2%
    Strong
  • Net Debt / EBITDA
    2.12x
    0.22x3.71x
    Near median
  • Dividend Yield
    1.0%
    0.2%5.6%
    Low
  • Payout Ratio
    38.6%
    4.7%147.8%
    Low
  • Altman Z-Score
    4.05
    -6.0711.93
    Above average
Financial Analysis
|

Stock Analysis

AI-generated
Based on 2026-07-28 data

Company Overview

Ecolab provides solutions, technologies, and services related to water, hygiene, food safety, infection prevention, and operational improvement, and generates revenue from core businesses such as Food & Beverage and Institutional & Specialty, as well as from growth engines including Global High-Tech, Life Sciences, Ecolab Digital, and Pest Elimination. In Q2 fiscal 2026, Food & Beverage grew 7% and Institutional & Specialty grew 4%, while Life Sciences delivered growth of 15%, Ecolab Digital 27%, Pest Elimination 7%, and Global High-Tech 29%.

In Q2 fiscal 2026, revenue reached $4.4 billion, up 10% on a reported basis, with organic growth of 5%, pricing of 4%, and volume growth of 1%. Gross profit was $1.9 billion, and the reported gross margin was 44.1%, while net income reached $534.9 million and EPS per EDGAR was $1.90; adjusted diluted EPS was $2.09, up 11% year over year.

Revenue for the twelve months ended in fiscal 2026 was approximately $16.5 billion, compared with $16.1 billion in fiscal 2025, and net income in both periods was approximately $2.1 billion. The mix is gradually shifting toward faster-growing activities: core businesses represented approximately 70% of 2025 sales, growth engines approximately 15%, and underperforming businesses approximately 15%; management expects growth engines to approach 25% of sales in 2027.

What's Driving the Stock

  • On 2026-07-28, Ecolab raised its adjusted EPS outlook for fiscal 2026 to a range of $8.05–$8.25, equivalent to growth of 7%–10%, after delivering $2.09 in Q2 fiscal 2026 and organic sales growth of 5%.
  • Global High-Tech has become the company's largest growth engine; it grew 29% in Q2 fiscal 2026, and its combined annualized sales with Ovivo and CoolIT approached $1.5 billion, divided approximately equally at $500 million each among Ecolab's existing business, Ovivo, and CoolIT. The company targets annual growth exceeding 25% to reach $4 billion in sales and a 25% operating income margin by 2030.
  • Ecolab closed the acquisition of CoolIT on 2026-07-02 in a transaction valued at $4.75 billion, adding direct-to-chip liquid-cooling technologies to its water solutions and 3D TRASAR digital control. CoolIT's sales before the acquisition had grown by more than 100% since the beginning of fiscal 2026, and Ecolab says the addition expands the sales opportunity within the data center to between three and five times the previous opportunity.
  • Life Sciences grew 15% in Q2 fiscal 2026, driven by market-share gains in Purolite bioprocessing, strength in the pharmaceutical and personal care businesses, and improved purification. The business achieved an operating income margin in the mid-twenties, and its size is now close to $1 billion compared with less than $100 million when it was established in 2017.
  • Ecolab Digital grew 27%, supported by adoption of DishIQ, AquaIQ, KitchenIQ, and CIPIQ, and the company targets long-term growth exceeding 20%. The business has an annualized revenue run rate of approximately $500 million, while management estimates the revenue opportunity from connecting all current customer locations and applications under a paid model at approximately $3 billion.
  • For the remaining two quarters of fiscal 2026, management expects organic sales growth of between 6% and 7% and an adjusted operating income margin of 19%, with pricing reaching 5%–6%. It also maintained its target of reaching a 20% operating income margin in 2027, followed by a return to an adjusted EPS growth trajectory of between 12% and 15% after fiscal 2026.

Buying & Selling Case

▲ Buying Case4 pts

  • +Ecolab combines improvement in its core businesses with accelerating growth engines; Food & Beverage grew 7%, Life Sciences 15%, Ecolab Digital 27%, and Global High-Tech 29% in Q2 fiscal 2026, reducing the dependence of growth on a single business.
  • +The Global High-Tech platform could transform the company's mix if it achieves its target of $4 billion in sales and a 25% operating income margin by 2030, compared with an annualized sales run rate approaching $1.5 billion in Q2 fiscal 2026. Integrating CoolIT with 3D TRASAR also gives Ecolab an offering that combines chip cooling and water and energy management within a single platform.
  • +The company demonstrated clear pricing power; pricing increased to 4% in Q2 fiscal 2026 and exited the quarter at 5%, helping to stabilize the organic gross margin despite higher commodity costs. Management expects pricing to reach 5%–6% in the second half of fiscal 2026 and to support an adjusted operating income margin of 19%.
  • +Life Sciences and Ecolab Digital provide two additional high-margin growth paths; Life Sciences recorded an operating income margin in the mid-twenties, while Ecolab Digital targets long-term growth exceeding 20% from an annualized revenue run rate of approximately $500 million.

▼ Selling Case

Valuation

The average analyst price target is $326.13, with a wide range between $275 and $360 and a consensus rating of “Buy”; the average is approximately 5.5% above the 52-week range high of $309.27, while the lowest target falls within the annual range of $243.15–$309.27. The breadth of the targets reflects meaningful disagreement over how much value CoolIT and the growth engines may generate, weighed against financing, amortization, and capital expenditure risks, and the data does not provide a valid earnings multiple for an additional comparison.

BuyAnalyst target: $326.13(+18.1%)

Figures in the text are as of 2026-08-27; the live price is shown at the top of the page.

FAQ

What drove Ecolab's results in Q2 fiscal 2026?

Revenue reached $4.4 billion, with total growth of 10% and organic growth of 5%, while adjusted diluted EPS increased 11% to $2.09. Pricing of 4% and volume growth of 1% helped stabilize the organic gross margin despite higher commodity costs. At the business level, Food & Beverage grew 7%, Life Sciences 15%, Ecolab Digital 27%, and Global High-Tech 29%.

How could the CoolIT acquisition affect Ecolab's growth?

Ecolab closed the acquisition of CoolIT on 2026-07-02, and the announced transaction value was $4.75 billion. CoolIT adds direct-to-chip liquid-cooling technologies to Ecolab's water solutions and 3D TRASAR, and the company says this increases the data-center sales opportunity to between three and five times the previous opportunity. With Ovivo and the existing business, Global High-Tech's annualized sales run rate is approaching $1.5 billion, and the company targets $4 billion and a 25% operating income margin by 2030. In contrast, the transaction's financing costs and non-cash amortization will pressure EPS in fiscal 2026.

What is Ecolab's outlook for the remainder of fiscal 2026?

On 2026-07-28, the company raised its adjusted EPS range to $8.05–$8.25, representing annual growth of 7%–10%. It expects organic sales growth of between 6% and 7% and an adjusted operating income margin of 19% in the second half of fiscal 2026. It also targets pricing of between 5% and 6% to offset high-single-digit commodity inflation, while volume growth is expected to remain close to 1% during the following quarters.

Earnings callEDGAR filings30-day newsInsider activity

Automated analysis for informational purposes only — not investment advice.

6 pts
  • −The CoolIT acquisition is valued at approximately $4.75 billion, and management acknowledged that financing costs and non-cash amortization will pressure EPS in fiscal 2026 and that return on invested capital will face short-term dilution. The company does not expect to return to its pre-acquisition organic return on invested capital level before 2028, making successful integration and continued CoolIT growth material financial factors.
  • −The company continues to face high-single-digit commodity inflation through the remainder of fiscal 2026, and margin protection depends on executing pricing of 5%–6%. The inclusion of Ovivo also creates approximately 60 basis points of pressure on the reported gross margin, so weak pricing or persistent input inflation could slow margin expansion.
  • −Volume growth remains limited; volumes increased by only 1% in Q2 fiscal 2026, with an approximately one-percentage-point negative impact from disruptions to customer operations caused by the conflict in the Middle East. Management expects volume growth to remain close to 1% during the following quarters, meaning that a significant portion of near-term growth depends on pricing and acquisitions.
  • −The growth engines require substantial upfront spending, as management expects capital expenditures to remain near 7% of sales during the next two years to support Global High-Tech and Life Sciences. In Life Sciences, management explained that the bioprocessing surge in Q2 fiscal 2026 will not necessarily recur every quarter, and that the reported margin in Q3 fiscal 2026 may decline to the high teens despite the underlying margin remaining in the mid-twenties.
  • −Approximately 15% of 2025 sales are still tied to businesses described as underperforming, which were recording low-single-digit sales declines and operating margins in the mid-teens. Despite stabilizing in 2026, the paper business experienced more than a year of contraction and customer plant closures, illustrating the sensitivity of part of the portfolio to industrial demand and customer consolidation cycles.
  • −Insider activity during the three months ended 2026-08-18 recorded net selling of $5.2 million, with four sales versus two purchases and a signal classified as strong_sell. This remains a weak trading signal on its own because insider sales may be prearranged, and the provided data does not explain the motivations behind those transactions.
Why has Global High-Tech become central to the ECL story?

Global High-Tech grew 29% in Q2 fiscal 2026, driven by demand for microelectronics and data centers associated with the buildout of artificial intelligence infrastructure. Its annualized sales run rate of approximately $1.5 billion consists of three parts of approximately $500 million each from Ecolab's existing business, Ovivo, and CoolIT. Management targets annual growth exceeding 25% until the business reaches $4 billion in sales in 2030. Technologies in demand include CoolIT 50-kilowatt cold plates, coolant distribution units, and the 3D TRASAR platform.

Can Ecolab reach a 20% operating income margin in 2027?

Management confirmed during the 2026-07-28 call that the 20% operating income margin target for 2027 remains unchanged. It expects the adjusted margin to reach 19% in the second half of fiscal 2026, benefiting from pricing, productivity, and a mix shift toward higher-growth businesses. The end of Nalco amortization will help offset part of the CoolIT amortization, but the first and second halves of 2027 may differ because of the timing of recognizing a full year of the acquisition. Therefore, achieving the target depends on continued growth in the core businesses and growth engines while absorbing CoolIT and Ovivo costs.

What are the key risks to monitor in ECL stock?

The most important financial risks are the execution of the $4.75 billion CoolIT acquisition, financing and amortization pressure, and the expectation that the previous organic return on invested capital level will not be restored before 2028. Operationally, the company expects high-single-digit commodity inflation, while volume growth was only 1% in Q2 fiscal 2026 and was affected by approximately one percentage point from Middle East disruptions. It also intends to keep capital expenditures near 7% of sales during the next two years, and the reported Life Sciences margin in Q3 fiscal 2026 may decline to the high teens after the exceptional bioprocessing surge in the previous quarter. The wide analyst target range between $275 and $360 adds evidence of differing expectations regarding the balance of these risks against Global High-Tech growth.